ADMA BIOLOGICS, INC. — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
ADMA reported Q3 2026 revenue of $141.1M (+5% YoY), with ASCENIV revenue at $124.7M (+31% YoY). Net income was $49.9M (+37% YoY); adjusted EBITDA $77.3M (+32% YoY). Gross margin expanded to 71% from 56% prior year. Company reiterated FY2026 revenue guidance of ≥$530M but raised adjusted earnings guidance: adjusted net income ≥$180M and adjusted EBITDA ≥$275M. YTD through Sept 30, repurchased 16.5M shares (6.3% of Dec 31, 2025 outstanding) for ~$180.3M; targeting $200M+ in 2026 buybacks. FDA provided constructive feedback on SG-001 pre-IND package; company expects IND submission and cites potential $300–500M annual revenue opportunity.
Why this rating
Strong ASCENIV growth (+31%), significant margin expansion (1,450 bps YoY), and raised earnings guidance meaningful for a $4.2B company. Active $200M+ buyback and regulatory progress on SG-001 pipeline are material. BIVIGAM decline offsets some momentum but stabilizing.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.